Clinical trial · Interventional
Behavioral Parenting Skills as a Novel Target for Improving Pediatric Medication Adherence: Study 3
NCT06074666CI-TRIAL-00109215recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The current study will assess the acceptability and feasibility of the CareMeds intervention with a larger sample (N = 100) across multiple sites in Buffalo, NY, and Atlanta, GA.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Lymphoblastic Leukemia, Pediatric | Childhood Acute Lymphoblastic Leukemia | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| CareMeds Intervention | Behavioral | — | UNRESOLVED |
| Usual Care Group | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- CareMeds Intervention
- description
- Participants complete the CareMeds parent training sessions during weeks 2, 3 and 4.
- interventionNames
- Behavioral: CareMeds Intervention
- type
- ACTIVE_COMPARATOR
- label
- Usual Care
- description
- Usual care consists of medical consultations and supportive care, The usual care group will serve as a delayed intervention/wait list group for which 3 parent training sessions will be offered during weeks 13 through 15.
- interventionNames
- Behavioral: Usual Care Group
Primary outcomes (1)
- measure
- Feasibility of the CareMeds 3 sessions
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 3 Years
- Maximum age
- 9 Years
Show eligibility criteria text
Inclusion Criteria: * Parent of a child who is diagnosed and being treated for any type of acute lymphoblastic leukemia (ALL) at a study site. * Parent has primary medication responsibility. * Pediatric patient aged 3-9 years * Child on therapy that includes home-based oral anti-cancer medication, such as 6-MP. * Parent has verbal English or Spanish fluency. * Participant must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure Exclusion Criteria: * Parent is unwilling or unable to follow protocol requirements
References
Publications (0)
Data not yet available
No reference posted for this study.